Pharmacogenomics of Stimulant Treatment Response
Recruiting now NCT06221358
Run by University of Calgary · for 6 to 24 · All sexes
What this study is about
The "Pharmacogenomics of Stimulant Treatment Response" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-24 with Attention deficit/hyperactivity disorder (ADHD).
Who can join (things the study team will check)
✅ You may be able to join if…
- Aged 6 - 24 years.
- Located in Western Canada (i.e., Alberta, British Columbia, Saskatchewan, Manitoba).
- Primary diagnosis of ADHD (all types).
- Starting Methylphenidate (excluding immediate release forms) treatment.
🚫 You may not be able to join if…
- Co-occurring psychotic, bipolar or eating disorders.
- Significant risk of suicide.
- An intellectual disability, or diagnosis of autism spectrum disorder (ASD) or tics/Tourette disorders.
- Past 12-month high-risk alcohol or substance use defined as monthly or more frequent use.
- Psychotherapy or brain stimulation-based therapy initiated within 8 weeks of referral or plans to initiate/change these types of therapies during the study
- History of liver or bone marrow (hematopoietic cell) transplant as these events can result in ambiguous genomic results.
Where this trial is running
- University of Calgary, Calgary, Alberta, Canada
Who to contact
Weng-Sam Siu, MSPT, MSc · 5875739747 · sam.siu@ucalgary.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06221358.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.